2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Revenue | $21M | $4.9M | $14M | $16M | $22M |
Cost of Revenue | $41M | $22M | $14M | $14M | $19M |
Gross Profit | -$19M | -$17M | -$811K | $2.7M | $3.1M |
Gross Profit % | -91% | -351% | -5.9% | 17% | 14% |
R&D Expenses | $38M | $20M | $27M | $40M | $49M |
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Net Income | -$116M | -$175M | -$302M | $142M | -$60M |
Dep. & Amort. | $1M | $1.1M | $1.2M | $985K | $1.3M |
Def. Tax | -$25M | $62M | $229M | $0 | $0 |
Stock Comp. | $8.1M | $7.3M | $9M | $8.6M | $8.7M |
Chg. in WC | -$13M | $14M | -$1.5M | -$2.5M | -$4M |
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Cash | $96M | $18M | $33M | $36M | $76M |
ST Investments | $0 | $0 | $96M | $108M | $34M |
Cash & ST Inv. | $96M | $18M | $130M | $144M | $109M |
Receivables | $10M | $3M | $2M | $2.5M | $4.5M |
Inventory | $17M | $5.3M | $6.3M | $7.3M | $8.8M |
Order intake for 2024 reached SEK 992 million, a 32% increase from the previous year, with 71% of the intake coming from trials, particularly in the U.S. market.
The Swedish and Dutch contracts, valued at €1,250 million combined, have over €1,000 million remaining in backlog, with rollouts and service phases extending into 2026 and beyond.
Full-year 2024 revenue was €371 million, with recurring revenue accounting for 59% of total revenue, despite challenges such as legislative changes in Iowa impacting revenue by DKK 20 million.
Investments in 2024 totaled €75 million, including €24 million for U.S. operations and €44 million to acquire a minority stake in a U.S. entity, with similar investment levels expected in 2025.
The company revised its timeline for achieving €1 billion in revenue with a 15% EBITDA margin to beyond 2025, now targeting an EBITDA margin of 12-14% for 2025.